Conestat Alfa (Ruconest)

Conestat alfa is a recombinant version of a human protein — C1 esterase inhibitor — approved to stop an acute hereditary angioedema attack. What makes it unusual isn't its mechanism, which is the same one two older plasma-derived drugs already used; it's where it comes from: the protein is purified from the milk of genetically engineered rabbits. A real pivotal trial backs the approved use. A later attempt to expand that approval to preventing attacks, rather than just treating them, was rejected by the FDA in 2018 and was never revived.

The same target two other drugs on this site already treat

Hereditary angioedema (HAE) is a rare genetic disorder, usually caused by a deficiency or dysfunction of C1 esterase inhibitor (C1-INH), a protein that normally restrains the kallikrein-bradykinin pathway. Without enough working C1-INH, that pathway runs unchecked, bradykinin builds up, and patients develop sudden, painful swelling attacks — in the skin, the gut, or, most dangerously, the airway. This site already covers two other approved drugs for acute HAE attacks that work further downstream in the same pathway: icatibant, which blocks the bradykinin receptor directly, and ecallantide, which inhibits kallikrein, the enzyme that generates bradykinin in the first place. Conestat alfa takes the most direct route of the three: rather than blocking a downstream consequence of the deficiency, it replaces the missing or malfunctioning C1-INH protein itself.

What makes it different: rabbit milk, not human plasma or blood

Two older C1-INH replacement drugs, Berinert and Cinryze, are purified directly from pooled human donor plasma — effective, but carrying the same theoretical blood-borne-pathogen and limited-supply concerns as any plasma-derived biologic. Conestat alfa is different: it is produced recombinantly in the mammary glands of rabbits that have been genetically engineered to carry the human C1-INH gene, purified from their milk, and formulated as a lyophilized powder reconstituted for slow IV injection. It is the first, and remains the only, plasma-free recombinant C1-INH approved for HAE. Because of its animal-derived production, the label carries a specific contraindication for patients with a known allergy to rabbits or rabbit-derived products — a real, mechanism-specific risk that has no equivalent in the plasma-derived alternatives.

The pivotal trial behind the approval

The trial supporting approval pooled results across dose-ranging and confirmatory studies of adults and adolescents treated for an acute HAE attack, comparing conestat alfa against placebo (saline). The median time to beginning of symptom relief was 66 minutes with the approved 100 U/kg dose, compared with 495 minutes (over 8 hours) on placebo — a large, statistically significant difference (Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, Haase G, Kaufman L, Hack CE, "Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema," J Allergy Clin Immunol 2010;126(4):821-827, PMID 20920772).¹ That trial, together with a further multicenter study in 44 adult and adolescent patients across 170 treated attacks, supported both the 2010 EU approval and the 2014 FDA approval for adults and adolescents.

The 2018 rejection: an approval that didn't expand

This is a narrower, less dramatic regulatory story than a full drug withdrawal or a failed pivotal trial — the original, currently marketed use was never in question — but it is a real rejection worth being accurate about: a company tried to expand an approved drug's label into a new, larger use case, the regulator said the evidence wasn't there yet, and the attempt was not revived. Patients and prescribers considering conestat alfa for prevention rather than acute treatment should know that use is off-label, not FDA-approved.

Current status

Conestat alfa remains marketed by Pharming Group as Ruconest in the US and Europe, prescribed for acute HAE attacks in adults and adolescents, self-administered by trained patients or given by a clinician. It sits alongside icatibant and ecallantide as this site's third approved acute-HAE peptide/protein therapy, each working at a different point in the same pathway, each with its own genuine trade-offs in speed of onset, administration route, and (for conestat alfa specifically) a rabbit-allergy contraindication the other two don't share.